NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research...
Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as...
NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief...
Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this...
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic Drugs indicating only minor formatting comments on the proposed label for its preservative-free ketamine...
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory...
Hope Therapeutics (subsidiary of NRx Pharmaceuticals, Nasdaq: NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's...
The show also broadcasts across MENA and Latin America as sponsored programming.
NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including...
Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing...